Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJintanat Ananworanichen_US
dc.contributor.authorBernard Hirschelen_US
dc.contributor.authorSunee Sirivichayakulen_US
dc.contributor.authorSasiwimol Ubolyamen_US
dc.contributor.authorThidarat Jupimaien_US
dc.contributor.authorWisit Prasithsirikulen_US
dc.contributor.authorPloenchan Chetchotisakden_US
dc.contributor.authorSasisopin Kiertiburanakulen_US
dc.contributor.authorWarangkana Munsakulen_US
dc.contributor.authorPhitsanu Raksakulkarnen_US
dc.contributor.authorSomboon Tansuphasawadikulen_US
dc.contributor.authorMalte Schutzen_US
dc.contributor.authorWendy Snowdenen_US
dc.contributor.authorKiat Ruxrungthamen_US
dc.contributor.otherThe HIV Netherlands Australia Thailand Research Collaborationen_US
dc.contributor.otherHopitaux universitaires de Geneveen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherBamrasnaradura Infectious Disease Instituteen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherVajira Hospitalen_US
dc.contributor.otherSanpatong Hospitalen_US
dc.contributor.otherBuddhachinnaraj Hospitalen_US
dc.contributor.otherHoffmann-La Roche Inc.en_US
dc.contributor.otherRoche Products Limited UKen_US
dc.identifier.citationAntiviral Therapy. Vol.11, No.5 (2006), 631-635en_US
dc.description.abstractBackground: There are few data on the selection of resistance by ritonavir-boosted saquinavir (SQV/r), particularly in antiretroviral (ARV)-naive patients. Objective: To assess the incidence of virological failure and evolution of resistance in ARV-naive individuals receiving SQV/r in the induction phase of the Staccato trial. Methods: ARV-naive subjects (n=272) received SQV/r 1,600/100 mg once daily with two nucleoside reverse transcriptase inhibitors (NRTIs) for at least 24 weeks. Patients were defined as having virological failure (VF) when there were two consecutive HIV-1 RNA measurements >500 copies/ml after week 12. Viral genotypes (reverse transcriptase [RT] and protease [PRO]) were determined at baseline in all patients and as close as possible to the time of initial failure in patients experiencing VF. Results: VF was observed in 9/272 patients receiving SQV/r 1,600/100 mg once daily with two NRTIs (3.3%) and occurred 19-48 weeks after treatment initiation. Eight of these patients were evaluable at failure. No major PRO mutations were detected, but 2/8 displayed single new minor PRO substitutions (M36I, L1OI) at VF that were known or suspected not to have been present at baseline; both these substitutions exist as natural polymorphisms. A third patient displayed a single new RT mutation (M1841). Conclusions: SQV/r plus two NRTIs (1,600/100 mg once daily) is an effective initial treatment option for ARV-naive patients, resulting in a low rate of viral rebound (3.3%). Furthermore, no major protease mutations were detected following VF, suggesting that future treatment options are preserved. © 2006 International Medical Press.en_US
dc.rightsMahidol Universityen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleAbsence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinaviren_US
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.